Back

The epidemiology of long COVID in US adults two years after the start of the US SARS-CoV-2 pandemic

Robertson, M.; Qasmieh, S.; Kulkarni, S.; Teasdale, C. A.; Jones, H. E.; McNairy, M.; Borrell, L. N.; Nash, D.

2022-09-14 epidemiology
10.1101/2022.09.12.22279862 medRxiv
Show abstract

ObjectivesTo characterize prevalence and impact of long COVID. MethodsWe conducted a population-representative survey, June 30-July 2, 2022, of a random sample of 3,042 United States adults. Using questions developed by the United Kingdoms Office of National Statistics, we estimated the prevalence by sociodemographics, adjusting for gender and age. ResultsAn estimated 7.3% (95% CI: 6.1-8.5%) of all respondents reported long COVID, approximately 18,533,864 adults. One-quarter (25.3% [18.2-32.4%]) of respondents with long COVID reported their day-to-day activities were impacted a lot and 28.9% had SARS-CoV-2 infection >12 months ago. The prevalence of long COVID was higher among respondents who were female (aPR: 1.84 [1.40-2.42]), had comorbidities (aPR: 1.55 [1.19-2.00]) or were not (versus were) boosted (aPR: 1.67 [1.19-2.34]) or not vaccinated (versus boosted) (aPR: 1.41 (1.05-1.91)). ConclusionsWe observed a high burden of long COVID and substantial variability in prevalence of SARS-CoV-2. Population-based surveys are an important surveillance tool and supplement to ongoing efforts to monitor long COVID.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.